Literature DB >> 26775851

Optimizing selection of large animals for antibody production by screening immune response to standard vaccines.

Mary K Thompson1, Peter C Fridy1, Sarah Keegan2, Brian T Chait3, David Fenyö2, Michael P Rout4.   

Abstract

Antibodies made in large animals are integral to many biomedical research endeavors. Domesticated herd animals like goats, sheep, donkeys, horses and camelids all offer distinct advantages in antibody production. However, their cost of use is often prohibitive, especially where poor antigen response is commonplace; choosing a non-responsive animal can set a research program back or even prevent experiments from moving forward entirely. Over the course of production of antibodies from llamas, we found that some animals consistently produced a higher humoral antibody response than others, even to highly divergent antigens, as well as to their standard vaccines. Based on our initial data, we propose that these "high level responders" could be pre-selected by checking antibody titers against common vaccines given to domestic farm animals. Thus, time and money can be saved by reducing the chances of getting poor responding animals and minimizing the use of superfluous animals.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody generation; Antigen; Camelid antibody; Immunization; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 26775851      PMCID: PMC4769958          DOI: 10.1016/j.jim.2016.01.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  19 in total

1.  Review of Polyclonal Antibody Production Procedures in Mammals and Poultry.

Authors:  W. Carey Hanly; James E. Artwohl; B. Taylor Bennett
Journal:  ILAR J       Date:  1995

Review 2.  A road less travelled: large animal models in immunological research.

Authors:  Wayne R Hein; Philip J Griebel
Journal:  Nat Rev Immunol       Date:  2003-01       Impact factor: 53.106

Review 3.  Nanobodies: natural single-domain antibodies.

Authors:  Serge Muyldermans
Journal:  Annu Rev Biochem       Date:  2013-03-13       Impact factor: 23.643

4.  Antibody avidity in Yorkshire pigs of high and low immune response groups.

Authors:  G Appleyard; B N Wilkie; B W Kennedy; B A Mallard
Journal:  Vet Immunol Immunopathol       Date:  1992-03       Impact factor: 2.046

5.  Compendium of animal rabies prevention and control, 2011.

Authors: 
Journal:  MMWR Recomm Rep       Date:  2011-11-04

6.  Estimation of rotavirus immunoglobulin G antibodies in human serum samples by enzyme-linked immunosorbent assay: expression of results as units derived from a standard curve.

Authors:  R F Bishop; E Cipriani; J S Lund; G L Barnes; C S Hosking
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

7.  Global analyses of human immune variation reveal baseline predictors of postvaccination responses.

Authors:  John S Tsang; Pamela L Schwartzberg; Yuri Kotliarov; Angelique Biancotto; Zhi Xie; Ronald N Germain; Ena Wang; Matthew J Olnes; Manikandan Narayanan; Hana Golding; Susan Moir; Howard B Dickler; Shira Perl; Foo Cheung
Journal:  Cell       Date:  2014-04-10       Impact factor: 41.582

Review 8.  Heterologous antisera and antivenins are essential biologicals: perspectives on a worldwide crisis.

Authors:  H Wilde; P Thipkong; V Sitprija; N Chaiyabutr
Journal:  Ann Intern Med       Date:  1996-08-01       Impact factor: 25.391

Review 9.  Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century.

Authors:  Gregory A Poland; Richard B Kennedy; Brett A McKinney; Inna G Ovsyannikova; Nathaniel D Lambert; Robert M Jacobson; Ann L Oberg
Journal:  Semin Immunol       Date:  2013-06-05       Impact factor: 11.130

Review 10.  Properties, production, and applications of camelid single-domain antibody fragments.

Authors:  M M Harmsen; H J De Haard
Journal:  Appl Microbiol Biotechnol       Date:  2007-08-18       Impact factor: 4.813

View more
  4 in total

1.  Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2.

Authors:  Fred D Mast; Peter C Fridy; Natalia E Ketaren; Junjie Wang; Erica Y Jacobs; Jean Paul Olivier; Tanmoy Sanyal; Kelly R Molloy; Fabian Schmidt; Magda Rutkowska; Yiska Weisblum; Lucille M Rich; Elizabeth R Vanderwall; Nicolas Dambrauskas; Vladimir Vigdorovich; Sarah Keegan; Jacob B Jiler; Milana E Stein; Paul Dominic B Olinares; Theodora Hatziioannou; D Noah Sather; Jason S Debley; David Fenyö; Andrej Sali; Paul D Bieniasz; John D Aitchison; Brian T Chait; Michael P Rout
Journal:  bioRxiv       Date:  2021-04-10

2.  Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape.

Authors:  Fred D Mast; Peter C Fridy; Natalia E Ketaren; Junjie Wang; Erica Y Jacobs; Jean Paul Olivier; Tanmoy Sanyal; Kelly R Molloy; Fabian Schmidt; Magdalena Rutkowska; Yiska Weisblum; Lucille M Rich; Elizabeth R Vanderwall; Nicholas Dambrauskas; Vladimir Vigdorovich; Sarah Keegan; Jacob B Jiler; Milana E Stein; Paul Dominic B Olinares; Louis Herlands; Theodora Hatziioannou; D Noah Sather; Jason S Debley; David Fenyö; Andrej Sali; Paul D Bieniasz; John D Aitchison; Brian T Chait; Michael P Rout
Journal:  Elife       Date:  2021-12-07       Impact factor: 8.140

Review 3.  Lipoarabinomannan as a Point-of-Care Assay for Diagnosis of Tuberculosis: How Far Are We to Use It?

Authors:  Julio Flores; Juan Carlos Cancino; Leslie Chavez-Galan
Journal:  Front Microbiol       Date:  2021-04-15       Impact factor: 5.640

4.  Host genetic variation explains reduced protection of commercial vaccines against Piscirickettsia salmonis in Atlantic salmon.

Authors:  Carolina Figueroa; Pamela Veloso; Lenin Espin; Brian Dixon; Débora Torrealba; Islam Said Elalfy; Juan Manuel Afonso; Carlos Soto; Pablo Conejeros; José A Gallardo
Journal:  Sci Rep       Date:  2020-10-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.